USFDA completes inspection at Laurus Labs’ Unit 1&3 of Visakhapatnam facility

22 Nov 2019 Evaluate

US Food and Drug Administration (USFDA) has completed, pre-approval inspection (PAI) at Laurus Labs’ API manufacturing 1&3 Units, located at J N Pharma City, Parawada, Visakhapatnam in the state of Andhra Pradesh.

The inspection ended with three observations, which are procedural in nature and no data integrity issues were observed in the inspection. The inspection was carried out from November 18, 2019 to November 21, 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

586.40 15.60 (2.73%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.